Lyell Immunopharma Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | 122.6% | – | – | 141.4% | 718.4% | 10.4% | 139,066.6% | 9.5% | 7,733.8% | 16,811.1% | 20,416.0% | 38,900.0% | 167,466.7% | 37,700.0% | – | 45,690.9% | – | 39,187.5% | – | 39,950.0% | 116,600.0% | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | -22.6% | 100.0% | 100.0% | -41.4% | -618.4% | 89.6% | -138,966.6% | 90.5% | -7,633.8% | -16,711.1% | -20,316.0% | -38,800.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -116,500.0% | 100.0% | -8,537.0% | |
| 2,030.3% | 3,115.8% | 2,289.8% | 1,517.7% | 1,168.3% | 1,767.4% | 1,140.9% | 542.0% | 5,941.6% | 108.0% | 1,214,500.0% | 69.1% | 61,863.1% | 156,766.7% | 159,964.0% | 320,146.2% | 1,439,133.3% | 309,700.0% | 116,176.5% | 442,436.4% | 620,671.4% | 435,712.5% | 187,813.3% | 869,983.3% | 1,830,200.0% | 988,100.0% | 579,625.9% | |
| 707.0% | 306.7% | 1,268.2% | 643.1% | 688.4% | 727.2% | 771.0% | 1,129.4% | 6,224.4% | 85.2% | 869,466.7% | 0.1% | 29,660.0% | 70,481.5% | 62,028.0% | 101,284.6% | 449,800.0% | 94,276.9% | 34,614.7% | 132,018.2% | 200,657.1% | 122,325.0% | 71,246.7% | 176,933.3% | 477,750.0% | 239,400.0% | 149,755.6% | |
| 2,727.7% | 3,389.5% | 3,543.3% | 1,809.5% | 1,856.6% | 2,486.1% | 1,884.4% | 1,671.4% | 12,166.0% | 193.2% | 2,083,966.7% | 123.6% | 91,523.1% | 227,248.1% | 221,992.0% | 421,430.8% | 1,852,600.0% | 396,469.2% | 148,644.1% | 1,828,709.1% | 819,628.6% | 589,350.0% | 248,453.3% | 1,021,966.7% | 2,191,350.0% | 1,183,525.0% | 702,792.6% | |
| -2,627.7% | -3,289.5% | -3,443.3% | -1,709.5% | -1,879.3% | -2,386.1% | -1,784.4% | -1,712.8% | -12,784.4% | -103.6% | -2,222,933.3% | -33.1% | -99,156.9% | -243,959.3% | -242,308.0% | -460,230.8% | -1,852,500.0% | -396,369.2% | -148,544.1% | -1,828,609.1% | -819,528.6% | -589,250.0% | -248,353.3% | -1,021,866.7% | -2,307,850.0% | -1,183,425.0% | -711,329.6% | |
| 186.4% | 60.3% | 102.4% | 26.9% | 14.5% | 8.3% | 9.8% | 11.4% | 71.8% | 2.7% | 75,033.3% | 7.4% | 101,032.3% | 19,496.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -2,328.0% | -3,228.2% | -3,338.2% | -1,680.7% | -2,251.2% | -2,381.8% | -1,774.0% | -2,966.2% | -12,322.6% | -101.6% | -2,341,800.0% | -17.4% | -103,013.8% | -236,629.6% | -203,412.0% | -407,153.8% | -2,022,233.3% | -352,376.9% | -131,126.5% | -1,744,863.6% | -745,642.9% | -533,550.0% | -258,973.3% | -2,345,383.3% | -1,207,650.0% | -1,118,875.0% | -920,285.2% | |
| -186.4% | -60.3% | -102.4% | -55.7% | -14.5% | -8.3% | -9.8% | -11.4% | -78.1% | -2.7% | 127,233.3% | -5.1% | 101,032.3% | -8,670.4% | -26,432.0% | 38,563.0% | 166,024.1% | – | – | – | – | – | – | – | – | – | – | |
| -2,328.0% | -3,228.2% | -3,338.2% | -1,680.7% | -2,251.2% | -2,381.8% | -1,774.0% | -2,966.2% | -12,322.6% | -101.6% | -2,341,800.0% | -17.4% | -103,013.8% | -236,629.6% | -203,412.0% | -407,153.8% | -2,022,233.3% | -352,376.9% | -131,126.5% | -1,744,863.6% | -745,642.9% | -533,550.0% | -258,973.3% | -2,345,383.3% | -1,207,650.0% | -1,118,875.0% | -920,285.2% | |
| -2,565.9% | -3,258.6% | -3,340.1% | -1,983.4% | -2,128.6% | -2,267.3% | -1,625.6% | -2,824.8% | -11,604.2% | -91.2% | -2,202,733.3% | -7.9% | -95,280.0% | -219,818.5% | -182,996.0% | -368,253.8% | -1,854,766.7% | -314,676.9% | -117,361.8% | -524,000.0% | -696,485.7% | -532,025.0% | -241,866.7% | -2,305,433.3% | -1,091,050.0% | -1,063,325.0% | -885,037.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.